wild-type EGFR and ALK – Non-squamous with EGFR mutation (EGFR + ) – Non-squamous with ALK-EML4 rearrangement (ALK + )
Non-Small Cell Lung Cancer Treatment Resectable (Stages I, II, III) • Surgery is the treatment of choice • Radiation – In medically inoperable can be used with curative intent
Non-Small Cell Lung Cancer Treatment • Squamous histology – Gemcitabine + cisplatin • Most common adjuvant regimen – Cisplatin + etoposide Gems are square shape
Non-Small Cell Lung Cancer Treatment • Non-squamous with wild-type EGFR and ALK – First line • Carboplatin + paclitaxel + bevacizumab • Carboplatin + pemetrexed – Second-line • Docetaxel + ramucirumab • Nivolumab • Pembrolizumab
Non-Small Cell Lung Cancer Treatment - Genomics • EGFR + Mutations – Erlo tinib – A fat inib – Ge fit inib • ALK + Rearrangements – Crizotinib – Ceritinib
Non-Small Lung Cancer Maintenance Therapy • Maintenance therapy – One of the agents form primary regimen therapy or some other single agents • Patients with NCSLC non-squamous histology if responded to 4-6 cycles of chemotherapy Continue maintenance
You've reached the end of your free preview.
Want to read all 30 pages?
- Spring '17
- Non-small Cell Lung Cancer, Cell Lung Cancer Treatment